NCT05086978Enrolling by invitation
Novel Clinical Utility of Retinal Imaging in Patients With Heart Failure
Novel Clinical Utility of Retinal Imaging in Patients With Heart Failure: A Pilot Study
Source: ClinicalTrials.gov · Last updated 22 Jul 2026
Brief summary (registry, in English)
Endothelial dysfunction and microvascular disease have been shown to play an important role in both the development and progression of heart failure. Retinal imaging provides a unique opportunity to non-invasively assess retinal microcirculation. Leveraging the non-invasiveness and relative ease of use of retinal imaging, we propose to investigate its clinical utility in assessing endothelial/microvascular dysfunction across the spectrum of heart failure. We aim to test the hypothesis that the degree of abnormality in retinal vessels is associated with heart failure disease severity, endothelial/microvascular dysfunction, and, potentially, treatment responses.
- Status (registry)
- Enrolling by invitation
- Study type
- Observational
- Enrollment
- 250 (estimated)
- First submitted
- 28 Sept 2021
- Start date
- 1 Feb 2022
- Primary completion date
- Dec 2027
- Lead sponsor
- The Cleveland Clinic
- Diseases
- Heart failure
- NCT number
- NCT05086978
What you commit to
- Study type: Observational
- Planned participants: 250
- From 1 Feb 2022 to the primary completion date, Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- pregnancy or planned pregnancy; photosensitive epilepsy; significant ophthalmologic conditions such as cataract, glaucoma, blindness, or progressive diabetic retinopathy; having undergone retinal laser photocoagulation; any condition which, in the judgment of the investigator, would place a patient at undue risk by being enrolled in the trial, or cause inability to comply with the study.
Who the study is looking for
- 18 years or above; have been diagnosed with HF of any etiology or healthy control; able to provide informed consent and comply with study protocol; able to undergo retinal evaluation using a handheld, automated, non-mydriatric retinal camera; and able to provide written informed consent.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cleveland Clinic Coordinator of this site? Confirm its status | Cleveland | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.